Relevant bibliographies by topics / PET/SPECT imaging / Journal articles

Journal articles on the topic 'PET/SPECT imaging'

To see the other types of publications on this topic, follow the link: PET/SPECT imaging.
Author: Grafiati
Published: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'PET/SPECT imaging.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

ONO, Masahiro. "Molecular Imaging by PET/SPECT." YAKUGAKU ZASSHI 129, no. 3 (March 1, 2009): 279–87. http://dx.doi.org/10.1248/yakushi.129.279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chua, S. C., R. H. Ganatra, D. J. Green, and A. M. Groves. "Nuclear cardiology: myocardial perfusion imaging with SPECT and PET." Imaging 18, no. 3 (September 2006): 166–77. http://dx.doi.org/10.1259/imaging/20803801.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Joseph, U. "Functional Cerebral SPECT and PET Imaging." Journal of Nuclear Medicine 51, no. 8 (July 21, 2010): 1326–27. http://dx.doi.org/10.2967/jnumed.110.076901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gallezot, Jean-Dominique, Yihuan Lu, Mika Naganawa, and Richard E. Carson. "Parametric Imaging With PET and SPECT." IEEE Transactions on Radiation and Plasma Medical Sciences 4, no. 1 (January 2020): 1–23. http://dx.doi.org/10.1109/trpms.2019.2908633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pioro, Erik P. "Imaging: MRS/MRI/PET/SPECT: Pro." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (September 2002): S71. http://dx.doi.org/10.1080/146608202320374354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kalra, S., and DL Arnold. "Imaging: MRS, MRI, PET/SPECT: Con." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (September 2002): S73—S74. http://dx.doi.org/10.1080/146608202320374363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leigh, P. Nigel, Andrew Simmons, Steve Williams, Vicky Williams, Martin Turner, and David Brooks. "Imaging: MRS/MRI/PET/SPECT: Summary." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (September 2002): S75—S80. http://dx.doi.org/10.1080/146608202320374372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lammertsma, Adriaan A. "PET/SPECT: functional imaging beyond flow." Vision Research 41, no. 10-11 (May 2001): 1277–81. http://dx.doi.org/10.1016/s0042-6989(00)00262-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rangacharyulu, Chary, and Christine K. Roh. "Isotopes for combined PET/SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry 305, no. 1 (February 14, 2015): 87–92. http://dx.doi.org/10.1007/s10967-015-3945-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Valotassiou, Varvara, Anastasia Leondi, George Angelidis, Dimitrios Psimadas, and Panagiotis Georgoulias. "SPECT and PET Imaging of Meningiomas." Scientific World Journal 2012 (2012): 1–11. http://dx.doi.org/10.1100/2012/412580.

Full text
Abstract:
Meningiomas arise from the meningothelial cells of the arachnoid membranes. They are the most common primary intracranial neoplasms and represent about 20% of all intracranial tumors. They are usually diagnosed after the third decade of life and they are more frequent in women than in men. According to the World Health Organization (WHO) criteria, meningiomas can be classified into grade I meningiomas, which are benign, grade II (atypical) and grade III (anaplastic) meningiomas, which have a much more aggressive clinical behaviour. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are routinely used in the diagnostic workup of patients with meningiomas. Molecular Nuclear Medicine Imaging with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) could provide complementary information to CT and MRI. Various SPECT and PET tracers may provide information about cellular processes and biological characteristics of meningiomas. Therefore, SPECT and PET imaging could be used for the preoperative noninvasive diagnosis and differential diagnosis of meningiomas, prediction of tumor grade and tumor recurrence, response to treatment, target volume delineation for radiation therapy planning, and distinction between residual or recurrent tumour from scar tissue.
APA, Harvard, Vancouver, ISO, and other styles
11

Khorsand, A., G. Stix, S. Nekolla, A. Becherer, K. Kletter, R. Dudczak, H. Sochor, G. Maurer, G. Porenta, and S. Graf. "Attenuation correction for myocardial perfusion imaging." Nuklearmedizin 45, no. 04 (2006): 171–76. http://dx.doi.org/10.1055/s-0038-1625112.

Full text
Abstract:
SummaryAim: We investigated the impact of photon attenuation in myocardial perfusion imaging with SPECT and PET in patients with coronary artery disease. In fact, the regional tracer distribution can be quantitatively assessed by polar map analysis if the effects of photon attenuation are accounted for. PET imaging permits accurate measurement of and correction for photon attenuation, whereas results of attenuation correction in SPECT imaging have been inconsistent. Patients, methods: We compared photon attenuation in resting perfusion imaging studies with SPECT (99mTc-sestamibi) and PET (13N-ammonia) from 21 patients. Transaxial images were reconstructed with and without attenuation correction and reoriented into short axis images. Polar map analysis was utilized to generate regional tracer uptake in six anatomical segments. Results: Average segmental photon attenuation calculated as the ratio of counts in corrected and uncorrected images was 7.2 ± 1.4 in SPECT and 14.0 ± 3.1 in PET imaging (p <0.01). This attenuation factor was significantly related to body mass index for both methods (p <0.001). While attenuation correction for SPECT imaging did compensate for attenuation effects in the inferior wall (from –15% to +6% vs. PET), relative tracer uptake in the anterior wall in SPECT images was significantly reduced after attenuation correction (from –2% to –18% vs. PET, p <0.01). Conclusion: Differential effects of attenuation correction for myocardial SPECT perfusion imaging need to be considered when algorithms designed to compensate effects of photon attenuation in SPECT imaging are employed in clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
12

Kerstens, Vera S., and A. Varrone. "Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT." Clinical and Translational Imaging 8, no. 5 (September 15, 2020): 349–56. http://dx.doi.org/10.1007/s40336-020-00386-w.

Full text
Abstract:
Abstract Purpose The dopamine transporter (DAT) serves as biomarker for parkinsonian syndromes. DAT can be measured in vivo with single-photon emission computed tomography (SPECT) and positron emission tomography (PET). DAT-SPECT is the current clinical molecular imaging standard. However, PET has advantages over SPECT measurements, and PET radioligands with the necessary properties for clinical applications are on the rise. Therefore, it is time to review the role of DAT imaging with SPECT compared to PET. Methods PubMed and Web of Science were searched for relevant literature of the previous 10 years. Four topics for comparison were used: diagnostic accuracy, quantitative accuracy, logistics, and flexibility. Results There are a few studies directly comparing DAT-PET and DAT-SPECT. PET and SPECT both perform well in discriminating neurodegenerative from non-neurodegenerative parkinsonism. Clinical DAT-PET imaging seems feasible only recently, thanks to simplified DAT assessments and better availability of PET radioligands and systems. The higher resolution of PET makes more comprehensive assessments of disease progression in the basal ganglia possible. Additionally, it has the possibility of multimodal target assessment. Conclusion DAT-SPECT is established for differentiating degenerative from non-degenerative parkinsonism. For further differentiation within neurodegenerative Parkinsonian syndromes, DAT-PET has essential benefits. Nowadays, because of wider availability of PET systems and radioligand production centers, and the possibility to use simplified quantification methods, DAT-PET imaging is feasible for clinical use. Therefore, DAT-PET needs to be considered for a more active role in the clinic to take a step forward to a more comprehensive understanding and assessment of Parkinson’s disease.
APA, Harvard, Vancouver, ISO, and other styles
13

Khalil, Magdy M., Jordi L. Tremoleda, Tamer B. Bayomy, and Willy Gsell. "Molecular SPECT Imaging: An Overview." International Journal of Molecular Imaging 2011 (April 5, 2011): 1–15. http://dx.doi.org/10.1155/2011/796025.

Full text
Abstract:
Molecular imaging has witnessed a tremendous change over the last decade. Growing interest and emphasis are placed on this specialized technology represented by developing new scanners, pharmaceutical drugs, diagnostic agents, new therapeutic regimens, and ultimately, significant improvement of patient health care. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) have their signature on paving the way to molecular diagnostics and personalized medicine. The former will be the topic of the current paper where the authors address the current position of the molecular SPECT imaging among other imaging techniques, describing strengths and weaknesses, differences between SPECT and PET, and focusing on different SPECT designs and detection systems. Radiopharmaceutical compounds of clinical as well-preclinical interest have also been reviewed. Moreover, the last section covers several application, of SPECT imaging in many areas of disease detection and diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
14

Zhu, Lin, Karl Ploessl, and Hank F. Kung. "PET/SPECT imaging agents for neurodegenerative diseases." Chem. Soc. Rev. 43, no. 19 (2014): 6683–91. http://dx.doi.org/10.1039/c3cs60430f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Clanton, J., and M. P. Sandler. "Molecular Imaging: Radiopharmaceuticals for PET and SPECT." Journal of Nuclear Medicine 51, no. 4 (March 29, 2010): 660–61. http://dx.doi.org/10.2967/jnumed.109.072645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

LeBlanc, Amy K., and Kathelijne Peremans. "PET and SPECT Imaging in Veterinary Medicine." Seminars in Nuclear Medicine 44, no. 1 (January 2014): 47–56. http://dx.doi.org/10.1053/j.semnuclmed.2013.08.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Zhang, Jessica, Katie Suzanne Traylor, and James M. Mountz. "PET and SPECT Imaging of Brain Tumors." Seminars in Ultrasound, CT and MRI 41, no. 6 (December 2020): 530–40. http://dx.doi.org/10.1053/j.sult.2020.08.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Zeck, O. E., B. Fang, N. Mullani, L. L. Lamki, K. L. Gould, L. A. Kramer, C. S. Ha, and J. W. Walsh. "PET and SPECT Imaging for Stereotactic Localization." Stereotactic and Functional Neurosurgery 64, no. 1 (1995): 147–54. http://dx.doi.org/10.1159/000098774.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Zipursky, Robert B., Jeffrey H. Meyer, and N. Paul Verhoeff. "PET and SPECT Imaging in Psychiatric Disorders." Canadian Journal of Psychiatry 52, no. 3 (March 2007): 146–57. http://dx.doi.org/10.1177/070674370705200303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Beller, G. "Myocardial perfusion imaging agents: SPECT and PET." Journal of Nuclear Cardiology 11, no. 1 (February 2004): 71–86. http://dx.doi.org/10.1016/j.nuclcard.2003.12.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Valotassiou, Varvara, Julia Malamitsi, John Papatriantafyllou, Efthimios Dardiotis, Ioannis Tsougos, Dimitrios Psimadas, Sotiria Alexiou, George Hadjigeorgiou, and Panagiotis Georgoulias. "SPECT and PET imaging in Alzheimer’s disease." Annals of Nuclear Medicine 32, no. 9 (August 20, 2018): 583–93. http://dx.doi.org/10.1007/s12149-018-1292-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Dobrucki, Lawrence W., and Albert J. Sinusas. "PET and SPECT in cardiovascular molecular imaging." Nature Reviews Cardiology 7, no. 1 (November 24, 2009): 38–47. http://dx.doi.org/10.1038/nrcardio.2009.201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Freedman, G. "Cost Effectiveness of PET/SPECT Hybrid Imaging." Clinical Positron Imaging 1, no. 4 (1998): 258. http://dx.doi.org/10.1016/s1095-0397(98)00048-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Flotats, Albert, Philip Hasbak, Alberto Hidalgo, and Ruben Leta. "Cardiac SPECT-CT and PET-CT Imaging." Current Medical Imaging Reviews 7, no. 3 (August 1, 2011): 175–92. http://dx.doi.org/10.2174/157340511796411212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Pascu, Sofia, and Jon Dilworth. "Recent developments in PET and SPECT imaging." Journal of Labelled Compounds and Radiopharmaceuticals 57, no. 4 (April 2014): 191–94. http://dx.doi.org/10.1002/jlcr.3196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Shetty, Dinesh, Jae-Min Jeong, and Hyunsuk Shim. "Stroma Targeting Nuclear Imaging and Radiopharmaceuticals." International Journal of Molecular Imaging 2012 (May 21, 2012): 1–23. http://dx.doi.org/10.1155/2012/817682.

Full text
Abstract:
Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging (PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly useful for differentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions, identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful, proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT or MRI. When combined with coregistered CT data, [18F]fluorodeoxyglucose ([18F]FDG)-PET is particularly useful. However, [18F]FDG is not a target-specific PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for additional applications of tumor imaging and therapy.
APA, Harvard, Vancouver, ISO, and other styles
27

Rice, Mitchell, Matthew Krosin, and Paul Haste. "Post Yttrium-90 Imaging." Seminars in Interventional Radiology 38, no. 04 (October 2021): 460–65. http://dx.doi.org/10.1055/s-0041-1735569.

Full text
Abstract:
AbstractTransarterial radioembolization with yttrium-90 (90Y) is a mainstay for the treatment of liver cancer. Imaging the distribution following delivery is a concept that dates back to the 1960s. As β particles are created during 90Y decay, bremsstrahlung radiation is created as the particles interact with tissues, allowing for imaging with a gamma camera. Inherent qualities of bremsstrahlung radiation make its imaging difficult. SPECT and SPECT/CT can be used but suffer from limitations related to low signal-to-noise bremsstrahlung radiation. However, with optimized imaging protocols, clinically adequate images can still be obtained. A finite but detectable number of positrons are also emitted during 90Y decay, and many studies have demonstrated the ability of commercial PET/CT and PET/MR scanners to image these positrons to understand 90Y distribution and help quantify dose. PET imaging has been proven to be superior to SPECT for quantitative imaging, and therefore will play an important role going forward as we try and better understand dose/response and dose/toxicity relationships to optimize personalized dosimetry. The availability of PET imaging will likely remain the biggest barrier to its use in routine post-90Y imaging; thus, SPECT/CT imaging with optimized protocols should be sufficient for most posttherapy subjective imaging.
APA, Harvard, Vancouver, ISO, and other styles
28

Kim, E. E. "Molecular Anatomic Imaging: PET/CT, PET/MR and SPECT/CT." Journal of Nuclear Medicine 56, no. 12 (October 1, 2015): 1965. http://dx.doi.org/10.2967/jnumed.115.167130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Maršić, Matej, Svjetlana Grbac-Ivanković, Tatjana Bogović Crnčić, Ivan Pribanić, Neva Girotto, and Tihana Klarica Gembić. "Hybrid SPECT/CT Somatostatin Receptor Imaging of Neuroendocrine Tumours." Medicina Fluminensis 57, no. 1 (March 1, 2021): 73–80. http://dx.doi.org/10.21860/medflum2021_365323.

Full text
Abstract:
Cilj: Cilj rada bio je procijeniti doprinos jednofotonske emisijske tomografije / kompjutorizirane tomografije somatostatinskih receptora (SR SPECT/CT) s 99mTc-EDDA/HYNIC-Tyr3-oktreotidom (99mTc-Tektrotyd) u dijagnostici i procjeni proširenosti bolesti kod pacijenata oboljelih od neuroendokrinih tumora (NET-ova). Ispitanici i metode: Retrospektivno je analizirano 120 SR SPECT/CT snimanja pacijenata s patohistološki dokazanim NET-om s obzirom na vizualizaciju primarnih lezija i metastaza. U 45 pacijenata učinjena je i pozitronska emisijska tomografija 18F-fluorodeoksiglukozom (18F-FDG PET/CT) te su nalazi uspoređeni s nalazima SR SPECT/CT-a i vrijednostima kromogranina A. Rezultati: Od 120 pacijenata 47 (39 %) je na SR SPECT/CT upućeno nakon odstranjenja primarne lezije. Od preostala 73 pacijenta (61 %), u 56 (77 %) primarni je tumor bio vidljiv SR SPECT/CT-om, a u 9 (12 %) poznata lezija nije akumulirala radiofarmak. U 8 (11 %) pacijenata s NET-om nepoznatog primarnog sijela nalaz je bio negativan. Od 68 (57 %) pacijenta s dokazanim metastazama, u njih 57 (84 %) bile su vidljive SR SPECT/CT-om, a u 11 (16 %) nisu akumulirale radiofarmak. Od 45 (38 %) pacijenata kojima je učinjen i 18F-FDG PET/CT, u 27 (60 %) detekcija primarnih lezija i metastaza bila je sukladna nalazu SR SPECT/CT-a. Osjetljivost SR SPECT/CT-a bila je 77 % za primarne lezije i 84 % za metastaze, a 18F-FDG PET/CT-a 75 % za primarne lezije i 76 % za metastaze. Vrijednosti kromogranina A nisu pokazale statistički signifikantnu korelaciju s nalazima slikovne dijagnostike. Zaključci: SR SPECT/CT ima visoku osjetljivost za detekciju NET-ova. Osim toga, potvrđena je komplementarnost s 18F-FDG PET/CT-om te kod pacijenata s negativnim nalazom SR SPECT/CT-a treba učiniti 18F-FDG PET/CT i obrnuto.
APA, Harvard, Vancouver, ISO, and other styles
30

Bailey, Dale L., and Kathy P. Willowson. "Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality." European Journal of Nuclear Medicine and Molecular Imaging 41, S1 (September 14, 2013): 17–25. http://dx.doi.org/10.1007/s00259-013-2542-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Gyöngyösi, M., H. Sochor, G. Maurer, G. Karanikas, R. Dudczak, E. Schuster, G. Porenta, S. Graf, and A. Khorsand. "Assessment of left ventricular volumes, ejection fraction and mass." Nuklearmedizin 50, no. 01 (2011): 9–14. http://dx.doi.org/10.3413/nukmed-0350-10-09.

Full text
Abstract:
Summary Aim: We compared and delineated possible differences of model-based analysis of ECGgated SPECT using 99mTc-sestamibi (Tc- SPECT) with ECG-gated 18F-fluorodeoxyglucose- PET (FDG-PET) for determination of enddiastolic (EDV) and end-systolic (ESV) cardiac volumes, left ventricular ejection fraction (LVEF), and myocardial mass (LVMM). Patients, methods: 24 patients (21 men; age: 54 ± 12years) with coronary artery disease underwent Tc-SPECT and FDG-PET imaging for evaluation of myocardial perfusion and viability. By using model-based analysis EDV, ESV, LVEF and LVMM were calculated from short axis images of both Tc-SPECT and FDGPET. Results: Left ventricular volumes by Tc- SPECT and FDG-PET were 176 ± 60 ml and 181 ± 59 ml for EDV, and 97 ± 44 ml and 103 ± 45 ml for ESV respectively, LVEF was 47 ± 8% by Tc-SPECT and 45 ± 9% by FDG-PET. The LVMM was 214 ± 40 g (Tc-SPECT) and 202 ± 43 g (FDG-PET) (all p = NS, paired t-test). A significant correlation was observed between Tc-SPECT and FDG-PET imaging for calculation of EDV (r = 0.93), ESV (r = 0.93), LVEF (r = 0.83) and LVMM (r = 0.72). Conclusion: ECG-gated Tc-SPECT and FDG-PET using two tracers with different characteristics (perfusion versus metabolism) showed close agreement concerning measurements of left ventricular volumes, contractile function and myocardial mass by using a model-based analysis.
APA, Harvard, Vancouver, ISO, and other styles
32

Dewulf, Jonatan, Karuna Adhikari, Christel Vangestel, Tim Van Den Wyngaert, and Filipe Elvas. "Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update." Cancers 12, no. 7 (July 11, 2020): 1868. http://dx.doi.org/10.3390/cancers12071868.

Full text
Abstract:
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to selectively visualize molecular targets. The nanomolar sensitivity of PET and SPECT combined with the high specificity and affinity of monoclonal antibodies have shown great potential in oncology imaging. Over the past decades a wide range of radio-isotopes have been developed into immuno-SPECT/PET imaging agents, made possible by novel conjugation strategies (e.g., site-specific labeling, click chemistry) and optimization and development of novel radiochemistry procedures. In addition, new strategies such as pretargeting and the use of antibody fragments have entered the field of immuno-PET/SPECT expanding the range of imaging applications. Non-invasive imaging techniques revealing tumor antigen biodistribution, expression and heterogeneity have the potential to contribute to disease diagnosis, therapy selection, patient stratification and therapy response prediction achieving personalized treatments for each patient and therefore assisting in clinical decision making.
APA, Harvard, Vancouver, ISO, and other styles
33

Al Badarin, Firas J., Paul S. Chan, John A. Spertus, Randall C. Thompson, Krishna K. Patel, Kevin F. Kennedy, and Timothy M. Bateman. "Temporal trends in test utilization and prevalence of ischaemia with positron emission tomography myocardial perfusion imaging." European Heart Journal - Cardiovascular Imaging 21, no. 3 (July 10, 2019): 318–25. http://dx.doi.org/10.1093/ehjci/jez159.

Full text
Abstract:
Abstract Aims To examine whether test utilization and prevalence of ischemia with positron emission tomography (PET) myocardial perfusion imaging (MPI) follow the previously described trends with single photon computed tomography (SPECT). Methods and results MPI studies performed between January 2003 and December 2017 were identified. Number of PET and SPECT MPI studies performed per year was determined. Trends in the proportion of studies showing any ischaemia (&gt;0%) with both modalities were compared before and after adjusting for baseline differences in patient characteristics using propensity scores. Interaction between imaging modality and year of testing was examined using modified Poisson regression. A total of 156 244 MPI studies were performed (30% PET and 70% SPECT). Between 2003 and 2017, the number of PET studies increased from 18 to 61 studies/1000 patient encounters, while SPECT volumes declined from 169 to 34/1000 patient encounters (P &lt; 0.001 for within-group comparisons). The prevalence of any ischaemia in SPECT-tested patients declined from 53.9% to 28.3% between 2003 and 2017, whereas ischaemia prevalence in PET-tested patients declined from 57.2% to 38.2% (P &lt; 0.001 for within-modality comparisons), with more PET studies showing ischaemia compared to SPECT [relative risk (RR) 1.44, 95% confidence interval (CI) 1.42–1.47; P &lt; 0.001]. After propensity score matching of 26 066 patients tested with SPECT with 26 066 patients tested with PET, the between-modality difference in ischaemia prevalence was significantly attenuated, with a slightly higher overall likelihood of detecting ischaemia with PET compared to SPECT (RR 1.08, 95% CI 1.05–1.11; P &lt; 0.001). Conclusions Utilization of PET MPI at a large-volume referral centre increased significantly between 2003 and 2017. Despite a significant decrease in the prevalence of ischaemia with SPECT and PET during the same period, the decline was less with PET, perhaps related to baseline risk of tested patients.
APA, Harvard, Vancouver, ISO, and other styles
34

Yang, Yunan, Hao Hong, Yin Zhang, and Weibo Cai. "Molecular Imaging of Proteases in Cancer." Cancer Growth and Metastasis 2 (January 2009): CGM.S2814. http://dx.doi.org/10.4137/cgm.s2814.

Full text
Abstract:
Proteases play important roles during tumor angiogenesis, invasion, and metastasis. Various molecular imaging techniques have been employed for protease imaging: optical (both fluorescence and bioluminescence), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET). In this review, we will summarize the current status of imaging proteases in cancer with these techniques. Optical imaging of proteases, in particular with fluorescence, is the most intensively validated and many of the imaging probes are already commercially available. It is generally agreed that the use of activatable probes is the most accurate and appropriate means for measuring protease activity. Molecular imaging of proteases with other techniques (i.e. MRI, SPECT, and PET) has not been well-documented in the literature which certainly deserves much future effort. Optical imaging and molecular MRI of protease activity has very limited potential for clinical investigation. PET/SPECT imaging is suitable for clinical investigation; however the optimal probes for PET/SPECT imaging of proteases in cancer have yet to be developed. Successful development of protease imaging probes with optimal in vivo stability, tumor targeting efficacy, and desirable pharmacokinetics for clinical translation will eventually improve cancer patient management. Not limited to cancer, these protease-targeted imaging probes will also have broad applications in other diseases such as arthritis, atherosclerosis, and myocardial infarction.
APA, Harvard, Vancouver, ISO, and other styles
35

Kim, Sunhee, and James M. Mountz. "SPECT Imaging of Epilepsy: An Overview and Comparison with F-18 FDG PET." International Journal of Molecular Imaging 2011 (July 14, 2011): 1–9. http://dx.doi.org/10.1155/2011/813028.

Full text
Abstract:
Epilepsy surgery is highly effective in treating refractory epilepsy, but requires accurate presurgical localization of the epileptogenic focus. Briefly, localization of the region of seizure onset traditionally dependents on seizure semiology, scalp EEG recordings and correlation with anatomical imaging modalities such as MRI. The introduction of noninvasive functional neuroimaging methods, including single-photon emission computed tomography (SPECT) and positron emission tomography (PET) has dramatically changed the method for presurgical epilepsy evaluation. These imaging modalities have become powerful tools for the investigation of brain function and are an essential part of the evaluation of epileptic patients. Of these methods, SPECT has the practical capacity to image blood flow functional changes that occur during seizures in the routine clinical setting. In this review we present the basic principles of epilepsy SPECT and PET imaging. We discuss the properties of the SPECT tracers to be used for this purpose and imaging acquisition protocols as well as the diagnostic performance of SPECT in addition to SPECT image analysis methods. This is followed by a discussion and comparison to F-18 FDG PET acquisition and imaging analysis methods.
APA, Harvard, Vancouver, ISO, and other styles
36

Takahashi, Miwako, Tomoko Tada, Tomomi Nakamura, Keitaro Koyama, and Toshimitsu Momose. "Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer’s Disease With Amyloid-PET." American Journal of Alzheimer's Disease & Other Dementias® 34, no. 5 (April 9, 2019): 314–21. http://dx.doi.org/10.1177/1533317519841192.

Full text
Abstract:
This study aimed to assess efficacy and limitations of regional cerebral blood flow imaging using single-photon emission computed tomography (rCBF-SPECT) in the diagnosis of Alzheimer’s disease (AD) with amyloid-positron emission tomography (amyloid-PET). Thirteen patients, who underwent both rCBF-SPECT and amyloid-PET after clinical diagnosis of AD or mild cognitive impairment, were retrospectively identified. The rCBF-SPECTs were classified into 4 grades, from typical AD pattern to no AD pattern of hypoperfusion; amyloid-beta (Aβ) positivity was assessed by amyloid-PET. Four patients were categorized into a typical AD pattern on rCBF-SPECT, and all were Aβ+. The other 9 patients did not exhibit a typical AD pattern; however, 4 were Aβ+. The Mini-Mental State Examination score and Clinical Dementia Rating scale were not significantly different between Aβ+ and Aβ– patients. A typical AD pattern on rCBF-SPECT can reflect Aβ+; however, if not, rCBF-SPECT has a limitation to predict amyloid pathology.
APA, Harvard, Vancouver, ISO, and other styles
37

Nayar, Jemimah, Kevin John, Anil Philip, Lina George, Anu George, Amos Lal, and Ajay Mishra. "A Review of Nuclear Imaging in Takotsubo Cardiomyopathy." Life 12, no. 10 (September 23, 2022): 1476. http://dx.doi.org/10.3390/life12101476.

Full text
Abstract:
Takotsubo cardiomyopathy or Takotsubo Syndrome (TTS) is a reversible left ventricular dysfunction syndrome that is increasingly being recognized. Recent advances in nuclear imaging have allowed us to study TTS in greater detail. We searched the PubMed and Medline databases and identified 53 publications with 221 patients reporting nuclear imaging findings in TTS. The age of the patients ranged from 17 to 87 years and were predominantly women (88.2%). The TTS variant was apical (typical) in 170 (76.9%), mid-ventricular in 23 (10.4%), and basal (reverse TTS) in 2 (0.9%). Cardiac perfusion was assessed using 99mTc sestamibi (MIBI) SPECT, 99mTc tetrofosmin SPECT, 201Tl SPECT, 82Rb PET, 201Tl SPECT, and 13N ammonia PET. Additional studies used were 123I MIBG SPECT, 123I BMIPP SPECT, 18F FDG PET, 67Ga citrate, and 11C hydroxy-ephedrine. A perfusion defect was seen in 69 (31.2%), and an inverse perfusion–metabolism mismatch (normal or near-normal perfusion with absent myocardial metabolic activity) was seen in 183 (82.8%) patients. Nuclear imaging has a significant role in evaluating, diagnosing, and prognosticating patients with TTS. As nuclear imaging technology evolves, we will surely gain more insights into this fascinating disorder.
APA, Harvard, Vancouver, ISO, and other styles
38

Bamford, Claire, Kirsty Olsen, Chris Davison, Nicky Barnett, Jim Lloyd, David Williams, Michael Firbank, Helen Mason, Cam Donaldson, and John O’Brien. "Is there a preference for PET or SPECT brain imaging in diagnosing dementia? The views of people with dementia, carers, and healthy controls." International Psychogeriatrics 28, no. 1 (July 15, 2015): 123–31. http://dx.doi.org/10.1017/s1041610215001039.

Full text
Abstract:
ABSTRACTBackground:Positron emission tomography (PET) and single photon emission computed tomography (SPECT) brain imaging are widely used as diagnostic tools for suspected dementia but no studies have directly compared participant views of the two procedures. We used a range of methods to explore preferences for PET and SPECT.Methods:Patients and controls (and accompanying carers) completed questionnaires immediately after undergoing PET and SPECT brain scans. Pulse rate data were collected during each scan. Scan attributes were prioritized using a card sorting exercise; carers and controls additionally answered willingness to pay (WTP) questions.Results:Few differences were found either between the scans or groups of participants, although carers marginally preferred SPECT. Diagnostic accuracy was prioritized over other scan characteristics. Mean heart rate during both scans was lower than baseline heart rate measured at home (p < 0.001).Conclusion:Most participants viewed PET and SPECT scans as roughly equivalent and did not have a preference for either scan. Carer preference for SPECT is likely to reflect their desire to be with the patient (routine practice for SPECT but not for PET), suggesting that they should be able to accompany vulnerable patients throughout imaging procedures wherever possible. Pulse rate data indicated that brain imaging was no more stressful than a home visit (HV) from a researcher. The data do not support the anecdotal view that PET is a more burdensome procedure and the use of PET or SPECT scans in dementia should be based on diagnostic accuracy of the technique.
APA, Harvard, Vancouver, ISO, and other styles
39

Dyrberg, Eva, Emil L. Larsen, Helle W. Hendel, and Henrik S. Thomsen. "Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT." Acta Radiologica 59, no. 9 (January 9, 2018): 1119–25. http://dx.doi.org/10.1177/0284185117751280.

Full text
Abstract:
Background Patient acceptance is an important factor when implementing imaging methods in clinical practice in line with availability, diagnostic accuracy, and cost-effectiveness. Purpose To investigate patient experience and acceptance regarding18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT), 11 C-choline-PET/CT, whole-body magnetic resonance imaging (WB-MRI), and 99mTc-hydroxymethane diphosphonate (HDP) single photon emission/computed tomography (SPECT/CT). Material and Methods One hundred and forty-nine patients with prostate cancer filled in a questionnaire regarding their experience of the imaging procedures they had been undergoing as part of a diagnostic accuracy study. Each patient had been undergoing a NaF-PET/CT, a WB-MRI, and either a SPECT/CT (group A) or a choline-PET/CT (group B). Results All four imaging methods received overall experience ratings at the favorable end of a 5-point Likert scale with the two PET/CT scans receiving marginally better average ratings (2.0) compared to SPECT/CT (2.2) and WB-MRI (2.3). The arm positioning above the head was the most uncomfortable part of the three nuclear medicine scans, whereas the acoustic noise was the most unpleasant part of the WB-MRI. The experience of staff instruction was relatively strongly correlated to the overall scanning experience of all four imaging modalities. Overall, the patients were willing to repeat the four imaging methods and NaF-PET/CT was the method most preferred in both groups. Conclusion Four imaging procedures were evaluated from the perspective of a selected group of prostate cancer patients. NaF-PET/CT, choline-PET/CT, WB-MRI, and bone SPECT/CT are well accepted imaging methods, and most patients prefer NaF-PET/CT.
APA, Harvard, Vancouver, ISO, and other styles
40

Karageorgou, Maria-Argyro, Penelope Bouziotis, Efstathios Stiliaris, and Dimosthenis Stamopoulos. "Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI." Nanomaterials 13, no. 3 (January 27, 2023): 503. http://dx.doi.org/10.3390/nano13030503.

Full text
Abstract:
During the last decades, the utilization of imaging modalities such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI) in every day clinical practice has enabled clinicians to diagnose diseases accurately at early stages. Radiolabeled iron oxide nanoparticles (RIONs) combine their intrinsic magnetic behavior with the extrinsic character of the radionuclide additive, so that they constitute a platform of multifaceted physical properties. Thus, at a practical level, RIONs serve as the physical parent of the so-called dual-modality contrast agents (DMCAs) utilized in SPECT/MRI and PET/MRI applications due to their ability to combine, at real time, the high sensitivity of SPECT or PET together with the high spatial resolution of MRI. This review focuses on the synthesis and in vivo investigation of both biodistribution and imaging efficacy of RIONs as potential SPECT/MRI or PET/MRI DMCAs.
APA, Harvard, Vancouver, ISO, and other styles
41

Barrios-Lopez, Brianda, and Kim Bergstrom. "Radiolabeled Sugars Used for PET and SPECT Imaging." Current Radiopharmaceuticals 9, no. 3 (December 12, 2016): 180–86. http://dx.doi.org/10.2174/1874471008666150525104725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Stoffey, Robert D. "Functional Cerebral SPECT and PET Imaging, 4th Edition." American Journal of Roentgenology 195, no. 5 (November 2010): W369. http://dx.doi.org/10.2214/ajr.10.4660.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

YONEKURA, YOSHIHARU. "FROM PET TO SPECT : EVOLUTION OF RADIONUCLIDE IMAGING." Japanese Journal of Radiological Technology 46, no. 11 (1990): 1822–29. http://dx.doi.org/10.6009/jjrt.kj00003321737.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Stolberg, Harald O. "What's New in Cardiac Imaging? SPECT, PET, MRI." Radiology 188, no. 3 (September 1993): 764. http://dx.doi.org/10.1148/radiology.188.3.764.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Cherry, Simon R. "Multimodality Imaging: Beyond PET/CT and SPECT/CT." Seminars in Nuclear Medicine 39, no. 5 (September 2009): 348–53. http://dx.doi.org/10.1053/j.semnuclmed.2009.03.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Klein, Ran, Emel Celiker-Guler, Benjamin H. Rotstein, and Robert A. deKemp. "PET and SPECT Tracers for Myocardial Perfusion Imaging." Seminars in Nuclear Medicine 50, no. 3 (May 2020): 208–18. http://dx.doi.org/10.1053/j.semnuclmed.2020.02.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Gray, Benjamin R., Atul Agarwal, Mark Tann, and Nicholas A. Koontz. "PET and SPECT Imaging of Brain Neoplasia Mimics." Seminars in Ultrasound, CT and MRI 41, no. 6 (December 2020): 541–50. http://dx.doi.org/10.1053/j.sult.2020.08.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Hall, Håkan, Lars Farde, Christer Halldin, Thomas Högberg, Stig Larsson, and Göran Sedvall. "Imaging of dopamine receptors using PET and SPECT." Neurochemistry International 20 (March 1992): 329–33. http://dx.doi.org/10.1016/0197-0186(92)90260-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Garcia, E. V., T. L. Faber, J. R. Galt, C. D. Cooke, and R. D. Folks. "Advances in nuclear emission PET and SPECT imaging." IEEE Engineering in Medicine and Biology Magazine 19, no. 5 (2000): 21–33. http://dx.doi.org/10.1109/51.870228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Antonini, Angelo, and Roberta DeNotaris. "PET and SPECT functional imaging in Parkinson's disease." Sleep Medicine 5, no. 2 (March 2004): 201–6. http://dx.doi.org/10.1016/j.sleep.2003.10.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'PET/SPECT imaging' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography